Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$2.57
EPS est.
$2.21
EPS surprise
+16.39%
1-day move
+7.65%
CVS Health's strong earnings per share performance exceeded expectations, contributing to a notable 7.65% increase in stock price. The company did not provide revenue figures or future guidance, leaving some uncertainty. Investors may view the EPS beat as a positive sign of operational efficiency or cost management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.57 | $2.21 | +16.39% |
| Revenue | N/A | $95.0B | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
CVS Health Corporation is a major player in the health care sector, providing a wide range of services including pharmacy benefits management, retail pharmacy, and health insurance. With a market cap of $105 billion, CVS is significant in shaping health care accessibility and affordability in the U.S.
Last quarter
In Q4 2025, CVS reported an EPS of $1.09, exceeding expectations by nearly 10%. However, the stock saw a slight decline the following day, indicating mixed market reactions.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+21.45%
Avg 1-day reaction
+3.82%
Analysts expect CVS to report solid earnings this quarter, with a consensus EPS of $2.21. The market is closely watching how the company navigates ongoing challenges in the health care sector.
Bull case
If CVS can exceed EPS expectations and show strong revenue growth, it may indicate robust demand for its services, leading to positive investor sentiment.
Bear case
Conversely, if CVS fails to meet earnings expectations or provides weak guidance, it could raise concerns about its ability to compete in a challenging market.
Key metrics to watch
EPS
$2.21Earnings per share (EPS) is a crucial measure of profitability and indicates how much profit is attributed to each share of stock.
Revenue
$95.0BTotal revenue reflects the company's overall sales performance and is essential for understanding growth trends.
The print will turn on these.
Q1
Will CVS achieve an EPS of at least $2.21 this quarter?
Meeting or exceeding this EPS target is crucial for maintaining investor confidence and could drive stock price appreciation.
Q2
What guidance will CVS provide for revenue growth in the upcoming quarters?
Clear guidance on revenue growth will help investors gauge the company's future performance and competitive positioning.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate CVS's ability to leverage its digital health initiatives, which could drive unexpected revenue growth.
Supporting evidence
Recent investments in digital health services could yield higher-than-expected customer engagement.
The options market indicates a potential for greater volatility, suggesting that significant movements are anticipated.
Historically, CVS has consistently beaten EPS estimates, indicating a potential for another positive surprise.
Key risk
If CVS's digital initiatives do not translate into tangible revenue growth, the current optimistic consensus could be challenged.
Pre-commit to what would confirm each case.
The market is debating CVS's ability to sustain growth amidst competitive pressures and changing health care dynamics.
Bull confirmed if
Achieving an EPS of $2.21 or higher with revenue exceeding $95 billion would confirm the bull case.
Bear confirmed if
An EPS below $2.10 or revenue under $91 billion would support the bear case.
What the market is pricing for the move.
Implied Move
±6.12%
Historical Avg
±5.7%
The options market is pricing in a moderate move around the earnings report, suggesting that investors anticipate some volatility.
Options are pricing ±6.6% while CVS has averaged ±5.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
32.4%
Smart-money positioning from the most recent 13F filings.
Institutional
90.83%
of float
Insider
0.06%
of float
Holders
2,660
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
123,223,409 sh · $10.8B
9.63%
-2.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CVS beats expectations, history suggests a potential stock increase of around 3.55%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline of about 16.84%, reflecting market disappointment and concerns about future performance.
The lines on the call that would change the story.
Vanguard Capital Management LLC
83,315,369 sh · $7.3B
6.51%
0.8%
Capital World Investors
74,951,955 sh · $6.6B
5.86%
-3.0%
State Street Corporation
60,283,408 sh · $5.3B
4.71%
1.6%
Dodge & Cox Inc.
50,012,765 sh · $4.4B
3.91%
-3.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.